More insights through: https://memoryprotection.org/what-is-the-lumipulse-ptau-217-beta-amyloid-42-ratio-test/
November 4, 2026 at 2:04 PM
More insights through: https://memoryprotection.org/what-is-the-lumipulse-ptau-217-beta-amyloid-42-ratio-test/
What does the Lumipulse pTau-217/Beta Amyloid 42 Ratio test look at?
It combines information from:
p-tau217
and
beta-amyloid 42
The result can help identify amyloid pathology associated with Alzheimer’s disease in appropriate clinical settings.
#MemoryProtection #AlzheimersDisease #CognitiveTesting
It combines information from:
p-tau217
and
beta-amyloid 42
The result can help identify amyloid pathology associated with Alzheimer’s disease in appropriate clinical settings.
#MemoryProtection #AlzheimersDisease #CognitiveTesting
November 4, 2026 at 2:04 PM
What does the Lumipulse pTau-217/Beta Amyloid 42 Ratio test look at?
It combines information from:
p-tau217
and
beta-amyloid 42
The result can help identify amyloid pathology associated with Alzheimer’s disease in appropriate clinical settings.
#MemoryProtection #AlzheimersDisease #CognitiveTesting
It combines information from:
p-tau217
and
beta-amyloid 42
The result can help identify amyloid pathology associated with Alzheimer’s disease in appropriate clinical settings.
#MemoryProtection #AlzheimersDisease #CognitiveTesting
2/ Same test name does not mean the same scale.
Different labs can use different methods and reference ranges. Keep the method with the result, not just the number.
Labcorp's own warning:
Different labs can use different methods and reference ranges. Keep the method with the result, not just the number.
Labcorp's own warning:
484390: Phosphorylated Tau 217 (pTau-217), Plasma Information
Labcorp test details for Phosphorylated Tau 217 (pTau-217), Plasma
www.labcorp.com
October 12, 2026 at 5:18 PM
2/ Same test name does not mean the same scale.
Different labs can use different methods and reference ranges. Keep the method with the result, not just the number.
Labcorp's own warning:
Different labs can use different methods and reference ranges. Keep the method with the result, not just the number.
Labcorp's own warning:
Fascinating study! Age-prediction models often overestimate young people's ages and underestimate older people's, so the age gap can partly reflect age itself. Was the speech age gap corrected for this, and does the link with pTau-217 still hold after the correction?
October 8, 2026 at 6:40 AM
Fascinating study! Age-prediction models often overestimate young people's ages and underestimate older people's, so the age gap can partly reflect age itself. Was the speech age gap corrected for this, and does the link with pTau-217 still hold after the correction?
🧵 3/3
The FDA cleared the first pTau-217 test in May 2025. Loop in a clinician first, counseling matters most here.
Want my free Brain Biomarker Guide? apoe4.link/ptau217
Education, not medical advice.
The FDA cleared the first pTau-217 test in May 2025. Loop in a clinician first, counseling matters most here.
Want my free Brain Biomarker Guide? apoe4.link/ptau217
Education, not medical advice.
September 23, 2026 at 9:10 PM
🧵 3/3
The FDA cleared the first pTau-217 test in May 2025. Loop in a clinician first, counseling matters most here.
Want my free Brain Biomarker Guide? apoe4.link/ptau217
Education, not medical advice.
The FDA cleared the first pTau-217 test in May 2025. Loop in a clinician first, counseling matters most here.
Want my free Brain Biomarker Guide? apoe4.link/ptau217
Education, not medical advice.
🧵 3/3
These markers appear 15-20 years before any symptom, a long head start. The 100% came from one cohort, not a universal guarantee.
Want my free Brain Biomarker Guide, what pTau-217, NfL and GFAP tell you? apoe4.link/earlymarkers
Education, not medical advice.
These markers appear 15-20 years before any symptom, a long head start. The 100% came from one cohort, not a universal guarantee.
Want my free Brain Biomarker Guide, what pTau-217, NfL and GFAP tell you? apoe4.link/earlymarkers
Education, not medical advice.
September 22, 2026 at 9:10 PM
🧵 3/3
These markers appear 15-20 years before any symptom, a long head start. The 100% came from one cohort, not a universal guarantee.
Want my free Brain Biomarker Guide, what pTau-217, NfL and GFAP tell you? apoe4.link/earlymarkers
Education, not medical advice.
These markers appear 15-20 years before any symptom, a long head start. The 100% came from one cohort, not a universal guarantee.
Want my free Brain Biomarker Guide, what pTau-217, NfL and GFAP tell you? apoe4.link/earlymarkers
Education, not medical advice.
Interconnected bimetallic PtAu nanowire networks as highly efficient electrocatalysts toward methanol and ethanol oxidation
ift.tt
September 20, 2026 at 4:45 PM
Interconnected bimetallic PtAu nanowire networks as highly efficient electrocatalysts toward methanol and ethanol oxidation
🇹🇷 Türkiye’de Alzheimer tanısı için kan testi uygulanmaya başladı
#Türkiye #Haber #Gündem #Alzheimer #KanTesti #GazetePencere
#Türkiye #Haber #Gündem #Alzheimer #KanTesti #GazetePencere
Alzheimer tanısında yeni dönem: Kan testi Türkiye’de uygulanmaya başladı
Alzheimer tanısına yardımcı “pTau-217” kan testi Türkiye’de bazı laboratuvarlarda uygulanmaya başladı. Uzmanlar, testin şimdilik zihinsel yakınması bulunan kişilerde hekim istemiyle kullanılmasını, sağlıklı kişilerde tarama amacıyla yapılmamasını öneriyor
www.gazetepencere.com
September 18, 2026 at 2:43 PM
🇹🇷 Türkiye’de Alzheimer tanısı için kan testi uygulanmaya başladı
#Türkiye #Haber #Gündem #Alzheimer #KanTesti #GazetePencere
#Türkiye #Haber #Gündem #Alzheimer #KanTesti #GazetePencere
【NfLとpTau217、ブラジル当局が血液検査を許可】
富士レビオのLumipulse G。NfL Bloodは神経軸索障害の指標。pTau 217 Plasmaは50歳以上で認知機能低下の兆候がある人のアミロイド病理評価を補助する。ブラジルANVISAの許可であり、国内適応の変更ではない。
富士レビオが血液バイオマーカー検査をブラジルへ拡大──ANVISAがNfLとpTau217アッセイを許可
stellanews.life/medicaldevic...
富士レビオのLumipulse G。NfL Bloodは神経軸索障害の指標。pTau 217 Plasmaは50歳以上で認知機能低下の兆候がある人のアミロイド病理評価を補助する。ブラジルANVISAの許可であり、国内適応の変更ではない。
富士レビオが血液バイオマーカー検査をブラジルへ拡大──ANVISAがNfLとpTau217アッセイを許可
stellanews.life/medicaldevic...
富士レビオが血液バイオマーカー検査をブラジルへ拡大──ANVISAがNfLとpTau217アッセイを許可
富士レビオは2026年9月14日、血液バイオマーカー検査「Lumipulse G NfL Blood」と「Lumipulse G pTau 217 Plasma」がブラジルの規制当局ANVISAから市販許可を取得したと発表した。両アッセイの特徴と臨床的位置づけを整理する。
stellanews.life
September 18, 2026 at 3:27 AM
【NfLとpTau217、ブラジル当局が血液検査を許可】
富士レビオのLumipulse G。NfL Bloodは神経軸索障害の指標。pTau 217 Plasmaは50歳以上で認知機能低下の兆候がある人のアミロイド病理評価を補助する。ブラジルANVISAの許可であり、国内適応の変更ではない。
富士レビオが血液バイオマーカー検査をブラジルへ拡大──ANVISAがNfLとpTau217アッセイを許可
stellanews.life/medicaldevic...
富士レビオのLumipulse G。NfL Bloodは神経軸索障害の指標。pTau 217 Plasmaは50歳以上で認知機能低下の兆候がある人のアミロイド病理評価を補助する。ブラジルANVISAの許可であり、国内適応の変更ではない。
富士レビオが血液バイオマーカー検査をブラジルへ拡大──ANVISAがNfLとpTau217アッセイを許可
stellanews.life/medicaldevic...
💵 #Forex
"GHENT, Belgium & TOKYO — H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use…"
"GHENT, Belgium & TOKYO — H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use…"
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma
financialpost.com
September 14, 2026 at 6:07 AM
Link to the paper, @thecovidinfoguy.bsky.social
🧠 Daily Feed of Brain Damage 🧠
www.sciencedirect.com/science/arti...
🧠 Daily Feed of Brain Damage 🧠
www.sciencedirect.com/science/arti...
September 10, 2026 at 8:59 AM
Link to the paper, @thecovidinfoguy.bsky.social
🧠 Daily Feed of Brain Damage 🧠
www.sciencedirect.com/science/arti...
🧠 Daily Feed of Brain Damage 🧠
www.sciencedirect.com/science/arti...
Article cited in the above piece: pubmed.ncbi.nlm.nih.gov/41494242/
Increased phosphorylated tau (pTau-181) is associated with neurological post-acute sequelae of coronavirus disease in essential workers: a prospective cohort study before and after COVID-19 onset - PubMed
This study was supported in part by funding from the Centers for Disease Control and Prevention (CDC/NIOSH CDC-75D30122c15522) and the National Institutes of Health (NIH/NIA AG049953).
pubmed.ncbi.nlm.nih.gov
September 9, 2026 at 3:39 PM
Article cited in the above piece: pubmed.ncbi.nlm.nih.gov/41494242/
Siloam-Roche luncurkan tes pTau 181 plasma guna deteksi dini Alzheimer - https://www.antaranews.com/berita/5734036/siloam-roche-luncurkan-tes-ptau-181-plasma-guna-deteksi-dini-alzheimer
Siloam-Roche luncurkan tes pTau 181 plasma guna deteksi dini Alzheimer
Siloam International Hospitals bersama Roche Diagnostics Indonesia meluncurkan layanan pemeriksaan biomarker darah pTau 181 Plasma di Indonesia untuk ...
www.antaranews.com
September 9, 2026 at 4:32 PM
Siloam-Roche luncurkan tes pTau 181 plasma guna deteksi dini Alzheimer - https://www.antaranews.com/berita/5734036/siloam-roche-luncurkan-tes-ptau-181-plasma-guna-deteksi-dini-alzheimer
We used a P364S tau virus to express pTau in the mouse LC. pTau accumulation induced time-dependent LC hyperactivity, neuroinflammation, transcriptome and proteome dysregulation, sleep spindle deficits, and prodromal Alzheimer's disease-like anxiety and compulsivity.
September 2, 2026 at 2:58 PM
We used a P364S tau virus to express pTau in the mouse LC. pTau accumulation induced time-dependent LC hyperactivity, neuroinflammation, transcriptome and proteome dysregulation, sleep spindle deficits, and prodromal Alzheimer's disease-like anxiety and compulsivity.
FDA cleared a blood test for Alzheimer's in symptomatic adults as young as 40, 97.6% accurate in trials. Australia's not far behind: TGA approved pTau blood tests in August.
FDA approves first Alzheimer's blood test for Americans as young as 40
In a move that could help drastically slow the advancement of Alzheimer's disease (AD), the US Food and Drug Administration (FDA) has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as young as 40 who have shown some potential cognitive symptoms of the condition.
newatlas.com
September 2, 2026 at 10:02 AM
FDA cleared a blood test for Alzheimer's in symptomatic adults as young as 40, 97.6% accurate in trials. Australia's not far behind: TGA approved pTau blood tests in August.
Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1
https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1
September 2, 2026 at 1:03 AM
Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1
https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1
Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1
September 1, 2026 at 11:25 PM
Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial https://www.medrxiv.org/content/10.64898/2026.08.27.26361535v1
💵 #Forex
"GHENT, Belgium & TOKYO — H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully…"
"GHENT, Belgium & TOKYO — H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully…"
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
financialpost.com
September 1, 2026 at 7:41 AM
Labcorp Launches Pioneer Blood Test for Detecting Alzheimer's Pathology in Healthcare Settings#United_States#Burlington#Labcorp#Alzheimer's#pTau-217
Labcorp Launches Pioneer Blood Test for Detecting Alzheimer's Pathology in Healthcare Settings
Labcorp has introduced Elecsys® pTau-217, the first FDA-cleared blood test for Alzheimer's, facilitating early diagnosis and better care for patients showing cognitive decline.
third-news.com
August 24, 2026 at 11:20 AM
Labcorp Launches Pioneer Blood Test for Detecting Alzheimer's Pathology in Healthcare Settings#United_States#Burlington#Labcorp#Alzheimer's#pTau-217
Member Spotlight: pTau-217, an early Alz's marker, rose in spinal fluid within hours of severe TBI, peaking near 18h. Higher early levels tracked with worse 6-month recovery. Study co-authored by BRAIN Center member Dr. John Williamson. pubmed.ncbi.nlm.nih.gov/40808925/ #UFBRAINCenter #TBI
August 19, 2026 at 7:54 PM
Member Spotlight: pTau-217, an early Alz's marker, rose in spinal fluid within hours of severe TBI, peaking near 18h. Higher early levels tracked with worse 6-month recovery. Study co-authored by BRAIN Center member Dr. John Williamson. pubmed.ncbi.nlm.nih.gov/40808925/ #UFBRAINCenter #TBI
verhindern, bevor sie sich im Körper festsetzen und zu einer chronischen Erkrankung führen kann.“
www.sciencedirect.com/science/arti...
news.stonybrookmedicine.edu/news/study-i...
www.sciencedirect.com/science/arti...
news.stonybrookmedicine.edu/news/study-i...
Increased phosphorylated tau (pTau-181) is associated with neurological post-acute sequelae of coronavirus disease in essential workers: a prospective cohort study before and after COVID-19 onset
The COVID-19 pandemic led to a spectrum of post-acute sequelae including several neurological complications including cognitive dysfunction labelled N…
www.sciencedirect.com
January 13, 2026 at 5:55 PM
verhindern, bevor sie sich im Körper festsetzen und zu einer chronischen Erkrankung führen kann.“
www.sciencedirect.com/science/arti...
news.stonybrookmedicine.edu/news/study-i...
www.sciencedirect.com/science/arti...
news.stonybrookmedicine.edu/news/study-i...
korrespondierender Autor und Professor am Department für Familien-, Bevölkerungs- und Präventivmedizin der Renaissance School of Medicine (RSOM). „Die Studienergebnisse deuten daher darauf hin, dass sich Long COVID mit der Zeit verschlimmern und zu Veränderungen der
January 13, 2026 at 5:45 PM
korrespondierender Autor und Professor am Department für Familien-, Bevölkerungs- und Präventivmedizin der Renaissance School of Medicine (RSOM). „Die Studienergebnisse deuten daher darauf hin, dass sich Long COVID mit der Zeit verschlimmern und zu Veränderungen der
Tau-Proteins (pTau-181) im Plasma um 59 Prozent, während oder nachdem neurokognitive Symptome auftraten, verglichen mit den Tau-Plasmaspiegeln vor COVID-19.
„Erhöhte Tau-Konzentrationen im Blut gelten als bekannter Biomarker für dauerhafte Hirnschäden“, so Sean Clouston,
„Erhöhte Tau-Konzentrationen im Blut gelten als bekannter Biomarker für dauerhafte Hirnschäden“, so Sean Clouston,
January 13, 2026 at 5:44 PM
Tau-Proteins (pTau-181) im Plasma um 59 Prozent, während oder nachdem neurokognitive Symptome auftraten, verglichen mit den Tau-Plasmaspiegeln vor COVID-19.
„Erhöhte Tau-Konzentrationen im Blut gelten als bekannter Biomarker für dauerhafte Hirnschäden“, so Sean Clouston,
„Erhöhte Tau-Konzentrationen im Blut gelten als bekannter Biomarker für dauerhafte Hirnschäden“, so Sean Clouston,
Schwindel, Gleichgewichtsstörungen, Veränderungen des Geschmacks- und Geruchssinns sowie Konzentrationsschwierigkeiten – entwickelten, zeigte einen signifikanten Anstieg des wichtigen Proteins Tau im Blutplasma. Tau kommt in Nerven und insbesondere im Gehirn vor. Erhöhte
January 13, 2026 at 5:42 PM
Schwindel, Gleichgewichtsstörungen, Veränderungen des Geschmacks- und Geruchssinns sowie Konzentrationsschwierigkeiten – entwickelten, zeigte einen signifikanten Anstieg des wichtigen Proteins Tau im Blutplasma. Tau kommt in Nerven und insbesondere im Gehirn vor. Erhöhte